查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017996

細胞治療技術市場：2026-2032年全球市場預測（按給藥方式、治療類型、生產流程、給藥方法、應用和最終用戶分類）

Cell Therapy Technologies Market by Offering, Therapy Type, Manufacturing Process, Delivery Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞治療技術市場價值將達到 36.5 億美元，到 2026 年將成長到 38.6 億美元，到 2032 年將達到 58.5 億美元，複合年成長率為 6.97%。

主要市場統計數據
基準年 2025 36.5億美元
預計年份：2026年 38.6億美元
預測年份 2032 58.5億美元
複合年成長率 (%) 6.97%

本書提供了一個權威的框架，用於理解科學突破、製造現實和商業性動態如何匯聚，從而決定細胞療法商業化的方向。

細胞療法正從實驗性治療方法發展成為一種系統性的臨床和商業性模式，對傳統的藥物模式提出了挑戰。過去十年，細胞製備、基因工程和自動化生產的科學進步，結合新的監管途徑和不斷成長的臨床證據，拓寬了細胞治療方法的適應症範圍。本文指出，技術創新本身並不能保證療法的普及應用，並概述了當前的生態系統，重點強調了可製造性、品質系統、報銷策略和供應鏈規模化等同樣重要的因素。

自動化、數據管理和治療方法的進步如何重塑整個細胞治療生態系統的製造模式和商業策略。

細胞治療領域的格局正沿著多個維度不斷演變，重新定義競爭優勢和營運重點。隨著臨床應用的推進，生產流程正從單一地點、小批量生產轉向擴充性、標準化的生產方式，強調自動化和封閉式系統。這種轉變降低了操作人員的差異性，縮短了產品上市時間，同時也提高了對設備互通性和耗材標準化的重視。同時，數據管理層正逐漸成為一項策略資產。能夠實現批次級追溯、品管分析和法規遵循文件編制的軟體和服務，對於業務永續營運至關重要。

基於各種情景，分析美國關稅趨勢到 2025 年的影響，以及供應鏈策略和資本計畫應如何調整以減輕累積風險。

美國關稅政策在2025年前的預期變化帶來了多重地緣政治和成本風險，相關人員必須積極應對。影響進口設備、專用耗材或原料的關稅可能導致資本項目延期或單位製造成本增加，即使企業試圖消化短期影響。要更理解累積影響，最好透過情境規劃，將原料採購、契約製造關係和庫存策略納入考量。在受關稅影響的情況下，擁有多元化供應商網路和國內製造管道的企業將更具優勢，而依賴單一進口管道的企業則可能面臨營運中斷。

全面的細分洞察，展示了產品陣容、治療方法類型、製造流程、給藥方法、適應症和最終用戶如何決定整個細胞治療價值鏈的策略重點。

基於細分市場的洞察揭示瞭如何最有效地將投資和營運重點放在加速專案進展的領域。根據所提供的產品，必須認知到耗材、儀器、軟體和服務如何發揮互補作用。耗材支援日常細胞處理和試劑一致性；生物反應器和細胞分析儀等儀器支援規模化生產和製程控制；而專注於資料管理和品管的軟體和服務則為可追溯性和法規遵循提供了數位化基礎。這些層面相互依存；儀器的選擇會影響耗材的使用，而資料系統對於檢驗製程效能至關重要。

美洲、歐洲、中東和非洲以及亞太地區在監管差異、臨床網路和基礎設施優勢方面的細微差別，如何影響投資地點和能力在地化地點的選擇？

區域環境對研發、生產和市場准入的策略選擇有顯著影響。在美洲，先進的臨床試驗網路、完善的先進療法報銷機制以及創業投資和企業資本的集中，都為快速的實用化提供了支持，但相關人員也必須應對複雜的支付方動態和細微的區域監管差異。在歐洲、中東和非洲（EMEA），管理體制和報銷環境各不相同，集中核准系統與各國特有的進入障礙並存。因此，在地化參與和因地制宜的定價策略至關重要。在亞太地區，政府支持力度的加大、對生產基礎設施的投資以及人力資源發展正在加速區域能力的提升，但知識產權方面的考慮和當地法規的成熟度因地區而異。

企業策略和夥伴關係模式的趨勢表明，整合能力、外包決策和監管參與正在塑造細胞治療領域的競爭優勢。

對企業行為的深入洞察揭示了影響競爭動態和合作機會的模式。主要企業正日益將內部能力與策略外包結合，以平衡控制力和速度。它們保留了流程開發和品質保證等核心能力，同時透過合作夥伴進行載體生產、填充和加工或專業分析等工作。那些早期投資於模組化、易於自動化的設備和標準化數據系統的公司，正在加速技術轉移並降低不同地區之間的差異。此類能力組合也吸引了尋求可預測擴展路徑的合作夥伴。

制定切實可行的策略重點，透過有針對性的投資和合作，增強製造業的韌性，加速市場進入速度，並降低商業化風險。

產業領導者必須將洞察轉化為優先行動，以降低營運風險並加速商業化進程。首先，他們必須投資於模組化自動化和經過驗證的設備，以實現跨工廠的可重複性，減少技術轉移摩擦並支援快速規模化生產。其次，他們必須制定正式的供應商多元化策略，並對關鍵耗材和設備子組件的國內替代品進行認證，以降低地緣政治風險和關稅相關干擾。第三，他們必須投資強大的數據和品管系統，以支援批次放行、監管申報以及整個分散式製造網路的可追溯性。

為了支持對細胞治療相關人員的可操作建議，我們開發了一種可解釋和可重複的調查方法，該方法整合了對高階主管的訪談、第二手資料和交叉檢驗。

本分析的調查方法結合了專家訪談和結構化二手資料，以確保研究的深度和實用性。一手資料包括對研發公司、契約製造製造商和醫院系統中生產部門的高階領導、品質保證經理、臨床營運經理和商業策略專家的深入訪談。透過這些對話，我們深入探討了影響供應商選擇的營運限制、技術採納促進因素和決策標準。二手資料包括科學文獻、監管指導文件、公司技術揭露和行業白皮書，用於檢驗技術的可行性和監管路徑。

策略整合表明，細胞療法的持續成功需要將科學創新、製造規範和市場驅動的商業化計劃整合起來。

總之，細胞治療領域正處於轉折點，科學成熟度、運作規範和商業性現實正在融合。僅靠治療方法的新穎性不足以惠及更多患者。還需要生產流程的可重複性、數位化品管系統以及能夠抵禦地緣政治和政策波動的供應鏈。將耗材、設備和軟體方面的投資與針對特定治療方法的生產選擇相結合的相關人員，將能夠實現更快、更可靠的專案進展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 細胞治療技術市場：依產品/服務分類

  • 消耗品
  • 裝置
    • 生物反應器
    • 細胞分析儀
  • 軟體服務
    • 資料管理
    • 品管

第9章 細胞治療技術市場：依治療方法

  • 異體細胞療法
    • 樹突狀細胞
    • 誘導性多功能幹細胞
    • 自然殺手細胞
  • 自體細胞療法
    • 造血幹細胞
    • 間質幹細胞
    • T細胞
  • 基因修飾細胞療法
    • CAR-T細胞療法
    • TCR（T細胞受體）療法

第10章 細胞治療技術市場：依製造流程分類

  • 細胞培養
    • 2D培養系統
    • 3D培養系統
  • 細胞增殖
    • 黏附培養
    • 懸浮培養
  • 細胞分離
    • 螢光活化細胞分選
    • 磁性細胞分選

第11章 細胞治療技術市場：依給藥方式分類

  • Ex Vivo
  • In vivo

第12章 細胞治療技術市場：依應用領域分類

  • 心血管疾病
    • 缺血性心臟疾病
    • 周邊動脈疾病
  • 肌肉骨骼疾病
    • 骨關節炎
    • 類風濕性關節炎
  • 神經退化性疾病
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 血癌
    • 固體癌
      • 乳癌
      • 肺癌
      • 攝護腺癌

第13章 細胞治療技術市場：依最終用戶分類

  • 生物製藥公司
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構
    • 政府附屬研究機構
    • 大學學術部門

第14章 細胞治療技術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 細胞治療技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 細胞療法技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國細胞療法技術市場

第18章 中國細胞治療技術市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Allogene Therapeutics Inc.
  • Atara Biotherapeutics, Inc.
  • Century Therapeutics, Inc.
  • Charles River Laboratories International, Inc.
  • Gamida Cell Ltd.
  • GE HealthCare
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Sartorius AG
  • Takara Bio Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vericel Corporation
Product Code: MRR-034230D3E636

The Cell Therapy Technologies Market was valued at USD 3.65 billion in 2025 and is projected to grow to USD 3.86 billion in 2026, with a CAGR of 6.97%, reaching USD 5.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.65 billion
Estimated Year [2026] USD 3.86 billion
Forecast Year [2032] USD 5.85 billion
CAGR (%) 6.97%

An authoritative framing of how scientific breakthroughs, manufacturing realities, and commercial dynamics converge to set the agenda for cell therapy commercialization

Cell therapies are evolving from experimental interventions into structured clinical and commercial paradigms that challenge conventional pharmaceutical models. Over the past decade, scientific advances in cell sourcing, genetic modification, and automated manufacturing have converged with new regulatory pathways and expanding clinical evidence to broaden the set of indications addressed by cell-based interventions. This introduction frames the current ecosystem by acknowledging that technical innovation alone does not guarantee adoption; equally important are manufacturability, quality systems, reimbursement strategy, and the ability to scale supply chains reliably.

In the wake of transformative clinical milestones, stakeholders now focus on the repeatability of processes, cost-to-deliver, and integration of data systems that ensure product traceability and patient safety. Investors and strategic partners increasingly assess platform applicability across therapy types, delivery methods, and end-user contexts. The industry is therefore transitioning toward modular solutions that combine consumables, specialized equipment, and software-enabled services to reduce cycle times and improve reproducibility. This introduction sets the scene for subsequent analysis by highlighting interdependencies across scientific, manufacturing, regulatory, and commercial domains, and underscores the imperative for cross-functional planning to convert technological promise into durable patient impact.

How advances in automation, data management, and therapeutic modality evolution are reshaping manufacturing models and commercial strategies across the cell therapy ecosystem

The landscape for cell therapies is shifting along multiple axes that will redefine competitive advantage and operational priorities. Clinical translation is driving a move from single-center, small-batch workflows toward scalable, standardized manufacturing approaches that emphasize automation and closed systems. This shift reduces operator variability and shortens time-to-release, but it also concentrates attention on equipment interoperability and consumable standardization. Concurrently, data management layers are emerging as strategic assets: software and services that enable batch-level traceability, quality control analytics, and regulatory-ready documentation are becoming essential to operational resilience.

Therapeutically, the sequence from autologous first-generation products to allogeneic and gene-modified modalities is reshaping supply chain design and commercial thinking. Allogeneic approaches increase the importance of upstream donor sourcing and inventory strategies, while gene-modified platforms expand the interface between cell therapy manufacturers and molecular biology suppliers. Geographic diversification of clinical trials and manufacturing facilities is another transformative trend, motivated by talent access, cost differentials, and regulatory landscapes. Taken together, these shifts signal a maturing industry that must balance scientific innovation with reproducible manufacturing and commercial scalability to unlock broader patient access.

Scenario-based implications of evolving United States tariffs for 2025 and how supply chain strategies and capital planning must adapt to mitigate cumulative risk

Anticipated changes in United States tariff policy for 2025 introduce a layer of geopolitical and cost risk that stakeholders must manage proactively. Tariffs that affect imported equipment, specialized consumables, or raw materials can translate into delayed capital projects and higher per-dose manufacturing costs, even when organizations seek to absorb short-term impacts. The cumulative effect is best understood through scenario planning that considers input sourcing, contract manufacturing relationships, and inventory strategies. In tariffs-impacted scenarios, firms with diversified supplier networks and onshore manufacturing options will be favored, while those reliant on single-source import channels may face operational disruptions.

Regulatory and procurement teams should evaluate supplier contracts for force majeure and pricing flexibility, while commercial leads should update reimbursement models to reflect potential cost inflation. Strategic responses include accelerating qualification of domestic suppliers, modularizing manufacturing to reduce reliance on large imported assemblies, and investing in technologies that lower consumable intensity per dose. In parallel, corporate development functions should reassess cross-border partnerships and consider regional manufacturing hubs that mitigate tariff exposure. By integrating tariff scenarios into capital planning and supplier risk assessments, organizations can preserve project timelines and protect margins against abrupt policy shifts.

Comprehensive segmentation insights showing how offerings, therapy types, manufacturing processes, delivery methods, applications, and end users define strategic priorities across the cell therapy value chain

Segmentation-driven insight reveals where investments and operational focus will most effectively accelerate program advancement. Based on offering, it is essential to recognize how consumables, equipment, and software and services play complementary roles: consumables underpin day-to-day cell handling and reagent consistency, equipment such as bioreactors and cell analyzers enable scale and process control, and software and services focused on data management and quality control provide the digital backbone for traceability and regulatory compliance. These layers are interdependent; equipment choices influence consumable footprints, and data systems are necessary to validate process performance.

Based on therapy type, differentiation between allogeneic cell therapy, autologous cell therapy, and gene-modified cell therapy determines manufacturing architecture. Allogeneic modalities, including dendritic cells, induced pluripotent stem cells, and natural killer cells, prioritize donor sourcing and batch banking approaches. Autologous therapies, such as hematopoietic stem cells, mesenchymal stem cells, and T-cells, demand patient-matched logistics and agile closed systems. Gene-modified treatments, exemplified by CAR-T and TCR therapies, layer genetic engineering steps that require integrated vector production and stringent quality control.

Based on manufacturing process, attention to cell culture, expansion, and separation illuminates capital and skills requirements. Cell culture systems that include 2D and 3D platforms drive upstream process design, while cell expansion choices between adherent and suspension culture affect scale economics. Cell separation technologies such as fluorescence-activated cell sorting and magnetic-activated cell sorting underpin purity and potency metrics. Based on delivery method, the ex vivo and in vivo dichotomy shapes cold-chain needs, administration logistics, and clinical workflow integration. Based on application, therapeutic focus across cardiovascular disease, musculoskeletal disorders, neurodegenerative diseases, and oncology informs target product profiles and clinical development pathways, with further granularity across ischemic heart disease, peripheral artery disease, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, hematological cancer, and a range of solid tumors including breast, lung, and prostate cancers influencing clinical endpoint selection. Based on end user, the ecosystem of biopharmaceutical companies, hospitals, and research institutes-where hospitals may be private or public and research institutes include government research centers and university academics-creates diverse procurement cycles and operational capabilities that must be matched by suppliers seeking commercial traction.

How regional regulatory nuance, clinical networks, and infrastructure strengths across the Americas, Europe Middle East & Africa, and Asia-Pacific inform where to invest and localize capabilities

Regional context materially affects strategic choices for development, manufacturing, and market access. In the Americas, advanced clinical trial networks, established reimbursement mechanisms for advanced therapies, and a concentration of venture and corporate capital support rapid translation, but stakeholders must also navigate complex payer dynamics and regional regulatory nuance. Europe, Middle East & Africa presents heterogeneous regulatory regimes and reimbursement environments where centralized approvals can coexist with country-level access barriers, creating an imperative for localized engagement and adaptive pricing strategies. In Asia-Pacific, growing government support, investments in manufacturing infrastructure, and talent development are accelerating regional capability, though intellectual property considerations and local regulatory maturity vary widely.

Given these differences, companies should align site selection, clinical trial designs, and partnership models to regional strengths. Manufacturing footprints can be hybrid: using near-market capacity in the Americas for rapid commercial launches, leveraging EMEA partners for regulatory alignment and access to diverse patient populations, and establishing scaled capabilities in Asia-Pacific to benefit from growing clinical demand and cost efficiencies. Cross-border coordination of regulatory submissions, supply chain logistics, and commercial strategy will be critical to sustain global programs and minimize time-to-patient across jurisdictions.

Patterns in company strategies and partnership models showing how integrated capabilities, outsourcing decisions, and regulatory engagement shape competitive advantage in cell therapy

Insights into company behavior reveal patterns that will influence competitive dynamics and partnership opportunities. Leading organizations increasingly combine in-house capabilities with strategic outsourcing to balance control and speed; they retain core competencies in process development and quality assurance while partnering for vector production, fill-finish, or specialized analytics. Companies that invest early in modular, automation-friendly equipment and harmonized data systems achieve faster tech transfer and reduce variability across sites. This capability set also attracts collaborators that seek predictable scale-up pathways.

Smaller innovators tend to concentrate on platform differentiation and clinical proof-of-concept while relying on contract development and manufacturing organizations for production. Strategic acquirers and corporate venture arms favor platforms that de-risk manufacturing or improve cost of goods, making manufacturing-focused technologies and quality automation attractive targets. Across the ecosystem, suppliers that offer integrated solutions-combining consumables, validated equipment, and quality-ready software-are best positioned to enter long-term supply agreements. Lastly, companies emphasizing regulatory engagement and early payer dialogue demonstrate higher resilience in navigating post-approval access challenges.

Actionable strategic priorities to fortify manufacturing resilience, accelerate market access, and de-risk commercialization through targeted investments and partnerships

Industry leaders must translate insight into prioritized actions that reduce operational risk and accelerate commercialization. First, align capital investments with modular automation and validated equipment that enable replication across sites, thereby lowering tech transfer friction and supporting rapid scale-up. Second, formalize supplier diversification strategies and qualify domestic alternatives for critical consumables and equipment subcomponents to mitigate geopolitical and tariff-related disruption. Third, invest in robust data management and quality control systems that support batch release, regulatory submissions, and traceability across decentralized manufacturing networks.

Additionally, pursue strategic partnerships that close capability gaps without diluting core intellectual property, and coordinate early with payers and regulatory authorities to define evidentiary pathways that reflect real-world use cases. Prioritize workforce development programs that upskill operators and quality professionals in cell therapy-specific practices, and create cross-functional commercialization playbooks that tie clinical development milestones to manufacturing scale triggers. Finally, adopt scenario-based financial planning that models supply chain shocks, reimbursement variability, and capital deployment options so that leadership teams can make decisive moves under uncertainty.

An explainable and reproducible methodology integrating executive interviews, secondary evidence, and cross-validation to underpin actionable recommendations for cell therapy stakeholders

The research methodology underpinning this analysis blends primary engagement with subject-matter experts and structured secondary synthesis to ensure both depth and practical relevance. Primary inputs include in-depth interviews with senior manufacturing leaders, quality assurance executives, clinical operations heads, and commercial strategy professionals from developers, contract manufacturers, and hospital systems. These conversations probe operational constraints, technology adoption drivers, and decision criteria that shape supplier selection. Secondary sources comprise scientific literature, regulatory guidance documents, company technical disclosures, and industry white papers used to validate technology feasibility and regulatory pathways.

Data triangulation reconciles qualitative insights with documented process descriptions and public regulatory filings. The approach emphasizes reproducibility by cross-checking vendor claims against independent technical evaluations and by capturing divergent viewpoints where consensus does not exist. Quality assurance workflows include peer review by analysts with process engineering and regulatory experience, and sensitivity checks that surface assumptions underpinning strategic recommendations. Where appropriate, limitations and potential bias are noted, and recommendations carry clear implementation considerations so that decision-makers can adapt findings to their specific organizational context.

A strategic synthesis demonstrating that durable success in cell therapy requires the integration of scientific innovation, manufacturing discipline, and market-aligned commercialization planning

In conclusion, the cell therapy sector stands at an inflection point where scientific maturity is converging with operational discipline and commercial pragmatism. The path to broader patient access requires more than therapeutic novelty; it demands manufacturing reproducibility, digitally enabled quality systems, and supply chains designed to withstand geopolitical and policy shifts. Stakeholders that synchronize investments in consumables, equipment, and software with therapy-specific manufacturing choices will realize faster and more reliable program progression.

Moreover, regional strategy, company-level partnership models, and proactive payer engagement will determine the pace of adoption across indications. By emphasizing modular automation, diversified sourcing, and data-driven quality control, organizations can reduce execution risk and improve the odds of sustainable commercialization. The cumulative message is clear: success in cell therapy will be driven by integrative strategies that connect scientific innovation to operational excellence and market-focused commercialization plans. This conclusion should guide leadership teams as they prioritize near-term investments and longer-term capability building.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Technologies Market, by Offering

  • 8.1. Consumables
  • 8.2. Equipment
    • 8.2.1. Bioreactors
    • 8.2.2. Cell Analyzers
  • 8.3. Software & Services
    • 8.3.1. Data Management
    • 8.3.2. Quality Control

9. Cell Therapy Technologies Market, by Therapy Type

  • 9.1. Allogeneic Cell Therapy
    • 9.1.1. Dendritic Cells
    • 9.1.2. Induced Pluripotent Stem Cells
    • 9.1.3. Natural Killer Cells
  • 9.2. Autologous Cell Therapy
    • 9.2.1. Hematopoietic Stem Cells
    • 9.2.2. Mesenchymal Stem Cells
    • 9.2.3. T-Cells
  • 9.3. Gene-Modified Cell Therapy
    • 9.3.1. CAR-T Cell Therapy
    • 9.3.2. TCR (T-Cell Receptor) Therapy

10. Cell Therapy Technologies Market, by Manufacturing Process

  • 10.1. Cell Culture
    • 10.1.1. 2D Culture Systems
    • 10.1.2. 3D Culture Systems
  • 10.2. Cell Expansion
    • 10.2.1. Adherent Culture
    • 10.2.2. Suspension Culture
  • 10.3. Cell Separation
    • 10.3.1. Fluorescence-Activated Cell Sorting
    • 10.3.2. Magnetic-Activated Cell Sorting

11. Cell Therapy Technologies Market, by Delivery Method

  • 11.1. Ex vivo
  • 11.2. In vivo

12. Cell Therapy Technologies Market, by Application

  • 12.1. Cardiovascular Disease
    • 12.1.1. Ischemic Heart Disease
    • 12.1.2. Peripheral Artery Disease
  • 12.2. Musculoskeletal Disorders
    • 12.2.1. Osteoarthritis
    • 12.2.2. Rheumatoid Arthritis
  • 12.3. Neurodegenerative Diseases
    • 12.3.1. Alzheimer's Disease
    • 12.3.2. Parkinson's Disease
  • 12.4. Oncology
    • 12.4.1. Hematological Cancer
    • 12.4.2. Solid Tumors
      • 12.4.2.1. Breast Cancer
      • 12.4.2.2. Lung Cancer
      • 12.4.2.3. Prostate Cancer

13. Cell Therapy Technologies Market, by End User

  • 13.1. Biopharmaceutical Companies
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals
  • 13.3. Research Institutes
    • 13.3.1. Government Research Centers
    • 13.3.2. University Academics

14. Cell Therapy Technologies Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cell Therapy Technologies Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cell Therapy Technologies Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cell Therapy Technologies Market

18. China Cell Therapy Technologies Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Allogene Therapeutics Inc.
  • 19.6. Atara Biotherapeutics, Inc.
  • 19.7. Century Therapeutics, Inc.
  • 19.8. Charles River Laboratories International, Inc.
  • 19.9. Gamida Cell Ltd.
  • 19.10. GE HealthCare
  • 19.11. Gilead Sciences, Inc.
  • 19.12. Johnson & Johnson Services, Inc.
  • 19.13. Novartis AG
  • 19.14. Sartorius AG
  • 19.15. Takara Bio Inc.
  • 19.16. Takeda Pharmaceutical Company Limited
  • 19.17. Thermo Fisher Scientific Inc.
  • 19.18. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY UNIVERSITY ACADEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY UNIVERSITY ACADEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY UNIVERSITY ACADEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET S